Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 6Neoplasm Metastasis 4Carcinoma, Squamous Cell 2Carcinoma 1Adenocarcinoma 1

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Radiation × Tumor-Agnostic × Clear all
NCT01523015 2013-02-05

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Medical University of Lublin

Phase 2/3 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡